EGP-437: Phase Ib/IIa started

EyeGate began an open-label, U.S. Phase Ib/IIa trial to evaluate 40 mg/mL EGP-437 on days 0, 4 and 14 in up to 20 patients with retinal vein occlusion (RVO), diabetic macular edema (DME) or postsurgic...